Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

4169.TW

SELLREMOVE

TCM Biotech International Corp. · Healthcare · Taiwan · $387M · Avg Vol: $1M/d

22
StockRank
Q
52
V
11
M
47
P/E (TTM)
475.0x
ROE
—
D/E
0.0x
Dividend %
0.2%
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

TCM Biotech is a small-scale biotechnology firm in Taiwan. It lacks the global scale, validated manufacturing platforms, and deep order books of high-conviction CDMOs, failing to fit our CDMO pricing power theme.

COMPANY DESCRIPTION

TCM Biotech International Corp. develops and markets molecular diagnostic kits, generic pharmaceuticals, and health supplements. The company holds proprietary technology in PCR-based diagnostic testing and maintains strong R&D collaborations with academic institutions. It is a niche biotechnology company focused on preventive medicine and infectious disease diagnostics in the Asia-Pacific region.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGR
Revenue—25.4M30.6M21.1M21.7M-5.1%
EPS0.000.010.010.01—113.0%
Shares—51.1M59.0M59.0M59.0M+15.5%
Debt—5.4M3.9M1.6M1.4M-36.9%
Equity—17.0M33.3M33.5M33.3M25.3%
Op CF—1.7M-1.2M5.3M1.2M-10.8%
Inv CF—-0.3M-0.1M-10.8M95,990—
Fin CF—-0.4M14.4M-3.1M-0.9M—
Loading...
PRICE (1Y)+18.6%
4.694.985.265.555.83May 12Jun 2Jun 23
SMA 50SMA 200
Close
$5.83
RSI (14)
71.3
52W High
$7.90
From 52W High
0.7%

SCORE BREAKDOWN

Quality
52
ROIC
2.1%48.7
ROE
—N/A
GP/Assets
26.6%59.8
Op. Margin
-16.1%27.2
FCF/Assets
—N/A
Piotroski
666.7
Int. Cover
26.8x72.3
D/E Ratio
0.01x85.5
Current Ratio
6.49x78.5
Value
11
P/E (TTM)
475.0x2.2
EV/EBITDA
4720.8x0.0
P/FCF
—N/A
P/B
8.1x15.1
P/S
14.4x20.9
Div Yield
0.2%4.8
Momentum
47
52W High %
74%52.3
RS 6M
-60%14.2
SMA 50/200
0.98x56.4
EPS Rev 4W
+97.7%99.6
EPS Rev 12W
—N/A
EPS Improve
—95.2
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$387M
P/E (Forward)
85.9x
Gross Margin
45.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4169.TW are excluded.

TickerCompanyMkt CapStockRankSignal
4169.TWTCM Biotech International Corp.(you)$387M22SELL
4147.TWOTaiMed Biologics Inc.$494M15STRONG SELL
4142.TWAdimmune Corporation$229M25SELL
6547.TWOMedigen Vaccine Biologics Corporation$468M32SELL
6589.TWEirGenix Inc.$443M8STRONG SELL
4157.TWOTaiGen Biopharmaceuticals Holdings Limited$193M16STRONG SELL
6794.TWUnicoCell Biomed Co., Ltd.$159M18STRONG SELL
4743.TWOOneness Biotech Co., Ltd.$726M11STRONG SELL
3176.TWOMedigen Biotechnology Corp.$146M28SELL
6535.TWOLumosa Therapeutics Co., Ltd.$532M2STRONG SELL

Peer medians: ROE 3.5% · P/E 16.0x · Gross margin 42.1%

TCM Biotech International Corp. (4169.TW) — Stock Score Summary

TCM Biotech International Corp. (4169.TW) has a MoatMap StockRank of 22/100 based on Quality (52/100), Value (11/100), and Momentum (47/100) factor scores. The current signal is SELL. TCM Biotech is a small-scale biotechnology firm in Taiwan. It lacks the global scale, validated manufacturing platforms, and deep order books of high-conviction CDMOs, failing to fit our CDMO pricing power theme.

TCM Biotech International Corp. develops and markets molecular diagnostic kits, generic pharmaceuticals, and health supplements. The company holds proprietary technology in PCR-based diagnostic testing and maintains strong R&D collaborations with academic institutions. It is a niche biotechnology company focused on preventive medicine and infectious disease diagnostics in the Asia-Pacific region.

Key Financial Metrics

Price$5.83
Market Cap$387M
P/E (TTM)475.00
P/E (Forward)85.88
Price/Book8.09
Return on Invested Capital2.1%
Debt/Equity1.50
Gross Margin45.3%
Operating Margin-16.1%
Dividend Yield0.2%

TCM Biotech International Corp. operates in the Biotechnology industry, part of the Healthcare sector (Taiwan).

Frequently Asked Questions

What is TCM Biotech International Corp.’s (4169.TW) StockRank?
MoatMap’s StockRank for TCM Biotech International Corp. (4169.TW) is 22/100, with a Sell signal. It is a composite of Quality (52), Value (11), and Momentum (47) factor ranks across MoatMap’s 20,000+ stock universe.
Does TCM Biotech International Corp. have an economic moat?
TCM Biotech International Corp. (4169.TW) has a Quality factor score of 52/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is TCM Biotech International Corp. a buy, hold, or sell?
MoatMap’s current signal for TCM Biotech International Corp. (4169.TW) is Sell, based on a StockRank of 22/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is TCM Biotech International Corp. in?
TCM Biotech International Corp. (4169.TW) operates in the Healthcare sector, specifically the Biotechnology industry (Taiwan).
Browse all ranked stocks4169.TW deep dive reportAI ChampionsHow we score stocksSense-check another stock